- In October 2024, Animal Dermatology Group, Inc. expanded its network by acquiring four dermatology specialty practices: Long Green Animal Dermatology, Nashville Veterinary Dermatology, Animal Dermatology & Allergy, and Dermatology & Allergy Clinic for Animals. This strategic move aims to enhance the company's presence in veterinary dermatology services
- In October 2024, Elanco Animal Health received FDA approval for Credelio Quattro, a monthly chewable tablet for dogs aged eight weeks and older. This oral medication treats and prevents infestations of fleas, ticks, roundworms, hookworms, and tapeworms, and also prevents heartworm disease. Credelio Quattro is expected to be launched in the first quarter of 2025
- In September 2024, the U.S. FDA approved Zenrelia (ilunocitinib), a once-daily oral Janus kinase (JAK) inhibitor developed by Elanco Animal Health. This medication is indicated for controlling pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged 12 months and older. Zenrelia offers a targeted approach to managing chronic skin conditions in canine
- In April 2024, the European Medicines Agency approved Lotimax, a chewable tablet containing lotilaner, for the treatment of flea, tick, and mite infestations in dogs. Lotimax is also indicated for treating demodicosis (caused by Demodex canis), providing a broad-spectrum solution for common parasitic skin conditions in canines
- In March 2024, the FDA approved Duotic, a combination of terbinafine (antifungal) and betamethasone acetate (glucocorticosteroid), for the treatment of otitis externa (ear infections) caused by yeast (Malassezia pachydermatis) in dogs. Duotic is notable for being the first FDA-approved veterinary otic medication targeting yeast-only infections without containing antibiotics
